

Requester: Industry

Date: April 2009

Purpose:

The data will be used internally only to populate patient forecasting models which we use for business planning. Business planning includes stock requirement forecasts, revenue forecasts and developing a general understanding of the market.

Table 1: CD4 category by treatment regimens (reproduction of ASR report table 7.1.1 – specifically CD4 re-categorisation of CD4)

	Regimen										Total ¹
	Rx NAIVE		MONO/DUAL		3+ NNRTI+PI,+/-NRTI		3+ NRTI+/-PI,NO NNRTI		3+ NRTI+NNRTI,NO PI		
	N	%	N	%	N	%	N	%	N	%	
<200	3	1.5	39	19.9	16	8.2	75	38.3	63	32.1	196
200-349	19	6.1	60	19.1	23	7.3	94	29.9	118	37.6	314
350-499	57	13.6	60	14.3	27	6.4	129	30.8	146	34.8	419
>500	182	21.4	99	11.6	40	4.7	208	24.5	321	37.8	850
Total	261	14.7	258	14.5	106	6.0	506	28.4	648	36.4	1779

1. Patients enrolled in AHOD and who have follow-up during 2007

Table 2: CD4 at the time of commencing antiretroviral treatment

Year	CD4+ (cells/ μ l)								Total ¹
	<200		200-349		350-499		>500		
	N	%	N	%	N	%	N	%	
<=2000	6	26.1	7	30.4	6	26.1	4	17.4	23
2001	5	23.8	10	47.6	4	19.0	2	9.5	21
2002	6	40.0	7	46.7	0	0.0	2	13.3	15
2003	3	17.6	7	41.2	4	23.5	3	17.6	17
2004	8	30.8	10	38.5	4	15.4	4	15.4	26
2005	5	26.3	8	42.1	3	15.8	3	15.8	19
2006	7	19.4	19	52.8	7	19.4	3	8.3	36
2007	10	33.3	14	46.7	3	10.0	3	10.0	30
Total	50	26.7	82	43.9	31	16.6	24	12.8	187

1. Patients needed to have commenced their first antiretroviral treatment (ART) AFTER having enrolled in AHOD; and also have a CD4 measure available within 1 year prior to commencing ART

Table 3: Top 25 combinations (3+ ARVs) in 2007 (reproduction of Table 7 in AHOD Annual Report)¹

Treatment combination	Frequency	Percent
ABC-LAM-NEV	85	5.48
TRUVADA-EFAV	80	5.16
TRUVADA-NEV	72	4.64
KIVEXA-NEV	66	4.26
CBV-NEV	61	3.93
KIVEXA-EFAV	55	3.55
CBV-EFAV	43	2.77
TRUVADA-ATAZ-RITON	42	2.71
ABC-LAM-EFAV	36	2.32
LAM-NEV-TENOF	32	2.06
LAM-EFAV-TENOF	29	1.87
KIVEXA-ATAZ-RITON	27	1.74
TRUVADA-KALETRA	27	1.74
TRIZIVIR	26	1.68
LAM-AZT-NEV	25	1.61
ABC-LAM-AZT	22	1.42
ABC-ATAZ-RITON-TENOF	20	1.29
LAM-D4t-NEV	19	1.23
EMTRIC-KALETRA-TENOF	17	1.1
LAM-ATAZ-RITON-TENOF	16	1.03
LAM-KALETRA-TENOF	16	1.03
EMTRIC-EFAV-TENOF	15	0.97
ABC-LAM-ATAZ-RITON	14	0.9
KIVEXA-KALETRA	13	0.84

1. 396 unique ART regimens; and a total of 1551 regimens recorded among 1316 patients on combo ART
2. Note: Some AHOD sites record fixed dose combination (fdc) drugs, such as Truvada, as their individual components (Emtricitabine and Tenofovir).